Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

Katsuhiro Yoshimura, MD; Naoki Inui, MD, PhD; Masato Karayama, MD, PhD; Yusuke Inoue, MD; Noriyuki Enomoto, MD, PhD; Tomoyuki Fujisawa, MD, PhD; Yutaro Nakamura, MD, PhD; Kengo Takeuchi, MD, PhD; Haruhiko Sugimura, MD, PhD; Takafumi Suda, MD, PhD

doi:10.1016/j.rmcr.2017.02.009

Respiratory Medicine Case Reports (Jan 2017)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

Katsuhiro Yoshimura, MD,
Naoki Inui, MD, PhD,
Masato Karayama, MD, PhD,
Yusuke Inoue, MD,
Noriyuki Enomoto, MD, PhD,
Tomoyuki Fujisawa, MD, PhD,
Yutaro Nakamura, MD, PhD,
Kengo Takeuchi, MD, PhD,
Haruhiko Sugimura, MD, PhD,
Takafumi Suda, MD, PhD

Affiliations

Katsuhiro Yoshimura, MD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Naoki Inui, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Masato Karayama, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yusuke Inoue, MD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Noriyuki Enomoto, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Tomoyuki Fujisawa, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yutaro Nakamura, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Kengo Takeuchi, MD, PhD: Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
Haruhiko Sugimura, MD, PhD: Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Takafumi Suda, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

DOI: https://doi.org/10.1016/j.rmcr.2017.02.009
Journal volume & issue: Vol. 20, no. C
pp. 160 – 163

Abstract

Read online

MET is a driver oncogene in non-small-cell lung cancer (NSCLC), and its amplification is associated with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A 56-year-old Japanese male with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation received erlotinib to which he responded for 12 months. After disease progression, re-biopsy analyses revealed newly developed MET amplification. Neither EGFR exon 20 T790M mutation nor MET exon 14 mutations were detected. The MET inhibitor, crizotinib, showed a dramatic response. This is the first report of successful crizotinib single-agent therapy in EGFR-mutant NSCLC that acquired MET amplification during erlotinib therapy.

Published in Respiratory Medicine Case Reports

ISSN: 2213-0071 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: http://www.journals.elsevier.com/respiratory-medicine-case-reports/

About the journal

Abstract

Keywords